Barclays
ALXO icon

Barclays’s ALX Oncology ALXO Stock Holding History

Barclays’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$66.8K Buy
48,046
+15,162
+46% +$29.3K ﹤0.01% 4475
2026
Q2 		$68.1K Buy
32,884
+22,369
+213% +$40K ﹤0.01% 4204
2026
Q1 		$21.1K Hold
10,515
– – ﹤0.01% 4568
2025
Q4 		$11.9K Sell
10,515
-52
-0.5% -$79 ﹤0.01% 4918
2025
Q3 		$19.3K Hold
10,567
– – ﹤0.01% 4939
2025
Q2 		$4.39K Sell
10,567
-37,462
-78% -$18.9K ﹤0.01% 4987
2025
Q1 		$29.9K Sell
48,029
-17,093
-26% -$20.5K ﹤0.01% 4724
2024
Q4 		$109K Buy
65,122
+5,620
+9% +$8.64K ﹤0.01% 4575
2024
Q3 		$108K Buy
59,502
+42,185
+244% +$157K ﹤0.01% 4553
2024
Q2 		$104K Sell
17,317
-11,318
-40% -$139K ﹤0.01% 3884
2024
Q1 		$319K Sell
28,635
-16,002
-36% -$225K ﹤0.01% 3853
2023
Q4 		$665K Buy
44,637
+17,673
+66% +$168K ﹤0.01% 3705
2023
Q3 		$129K Buy
26,964
+9,796
+57% +$53.2K ﹤0.01% 3495
2023
Q2 		$129K Buy
17,168
+1,621
+10% +$10.6K ﹤0.01% 3462
2023
Q1 		$70.3K Buy
15,547
+4,019
+35% +$30.4K ﹤0.01% 4338
2022
Q4 		$130K Buy
11,528
+4,851
+73% +$54.5K ﹤0.01% 4078
2022
Q3 		$64K Buy
6,677
+2,464
+58% +$28.7K ﹤0.01% 3700
2022
Q2 		$34K Sell
4,213
-494
-10% -$5.38K ﹤0.01% 4189
2022
Q1 		$80K Buy
+4,707
New +$80.4K ﹤0.01% 3889

Other funds holding ALXO

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
JSF Financial
JSF Financial Los Angeles, California $655M AUM 20.11% 1-Year Est. Return
Abel Hall LLC
Abel Hall LLC Baton Rouge, Louisiana $556M AUM 43.18% 1-Year Est. Return
Lido Advisors
Lido Advisors Los Angeles, California $39.1B AUM 20.96% 1-Year Est. Return

Barclays's ALXO Position: Q3 2026 in Review

Barclays increased its ALX Oncology (ALXO) stake by 46% in Q3 2026, buying an estimated $29.3K and bringing the position to 48,046 shares worth $66.8K. The position accounts for ﹤0.01% of the portfolio, ranked #4475.

Barclays first reported a position in ALXO in Q1 2022 and has held it in 19 quarters since. The position peaked at $665K in Q4 2023. 26 funds tracked by Wall St. Rank hold ALXO as of Q3 2026.

  • Barclays held 48,046 shares of ALX Oncology worth $66.8K as of Q3 2026.
  • Barclays bought 15,162 ALX Oncology shares in Q3 2026, an estimated $29.3K.
  • ALX Oncology made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #4475 holding.
  • Barclays first reported a position in ALX Oncology in Q1 2022 and has held it in 19 quarters since.
  • Barclays's ALX Oncology position peaked at $665K in Q4 2023.
  • 26 funds tracked by Wall St. Rank held ALX Oncology as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.